As Britain’s departure date from the European Union approaches, drugmakers are preparing for potential changes to regulatory procedures and border controls.

NIDA pharmacologist Michael Baumann explains how “unscrupulous vendors” hijacked compounds used in neuroscience and turned them into dangerous drugs.

The World Health Organization predicts the number of cases in Democratic Republic of Congo will rise up to 300 by July.  

Biotechs have developed enzyme replacements and genetically modified probiotics to treat patients with the rare metabolic disorder.

Lucemyra is the first non-opioid drug to be approved in the U.S. specifically for this purpose.

The scientists involved have hired lawyers to fight the conclusions of a recent investigation into some studies of Diovan in Japan.

Multidrug combinations lead to better results for cancer patients, but efficiently identifying them is proving difficult.

Pharmaceutical giant Sanofi to take over hemophilia drugmaker Biovertiv, while Celgene will buy cancer drugmaker Juno Therapeutics.

The immunotherapy, which targets CD22 on cancer cells rather than CD19, might prove useful in patients for whom previous T-cell treatments were unsuccessful.